Almac concludes commercial API manufacturing facility expansion plans

Wednesday, October 10, 2012 10:14 AM

In response to client requirements, global service provider Almac’s expansion of their API manufacturing facility at its European headquarters in Craigavon, U.K. is near completion, and will be operational by the end of the year. 

The upgrade includes installation of two 1,000L reactors and state-of-the-art pressure filter dryer, which allows production of GMP Active Pharmaceutical Ingredients (API) up to 150kg batch size.

“Almac’s investment has further demonstrated our goal of being the outsourcing partner of choice through all stages of clinical development,” said Denis Geffroy, vice president of business development, Almac. “We are delighted to have the scale to share the manufacturing journey with our clients from preclinical phase to full commercialization.”

Clients can also leverage Almac’s API and drug product integrated offering where API manufacture and finished drug production is carried out on the same site, ensuring reduction in costs and timelines whilst maintaining scientific continuity. Almac’s advantage of hosting all facilities on one site have led to the successful technology transfer of small molecule and peptide projects from lab development to large scale manufacture. 

Share:          
CWWeekly

April 13

Quintiles-Quest Diagnostics joint venture latest in CRO-central lab deals, more could be on horizon

Biotech companies raise record amount of capital in Q1

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs